Adoptive Transfer of Autologous T Cells Targeted to Prostate-Specific Membrane Antigen for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Full Title

Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) Back to top

Purpose

This phase I study will evaluate the safety and effectiveness of different doses of a patient’s own immune cells (T cells) which have been changed to help recognize and destroy his prostate cancer cells by targeting a protein called prostate-specific membrane antigen. The T cells are removed from the patient’s blood, modified with a gene in the laboratory so they are better able to recognize and kill prostate cancer cells, and then returned to the patient’s body. This gene is inserted into the T cells using a weakened virus. /

It is hoped that this approach will help each patient’s own T cells recognize his prostate cancer cells and possibly kill them.

Back to top

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic prostate cancer that has not yet been treated with chemotherapy. Patients may have had hormonal therapy.
  • Patients must have rising PSA levels and a serum testosterone level under 50 ng/mL.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Susan F. Slovin at 646-422-4470 or Dr. Howard Scher at 646-422-4330.

Back to top

Protocol

09-036

Phase

I

Investigator

Locations